Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MK-8353
i
Other names:
MK-8353, SCH 900353, SCH-900353, MK 8353
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Merck (MSD)
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
‹
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
ATG-017 (0)
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
ATG-017 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) (NCT03745989)
Phase 1b
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1b
Merck Sharp & Dohme LLC
Completed
Last update posted :
07/27/2023
Initiation :
02/22/2019
Primary completion :
03/19/2021
Completion :
03/19/2021
RAS
|
RAS mutation
|
Koselugo (selumetinib) • MK-8353
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) (NCT02972034)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
03/02/2023
Initiation :
01/13/2017
Primary completion :
12/02/2022
Completion :
12/02/2022
EGFR • MSI
|
EGFR mutation • RAS mutation
|
Keytruda (pembrolizumab) • MK-8353
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login